Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. The introduction of LA depot formulations provided a significant improvement in the acceptance of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunn, Ulf W, Gruca, Damian, Bacher, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639016/
https://www.ncbi.nlm.nih.gov/pubmed/23637525
http://dx.doi.org/10.2147/CIA.S27931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639016/
https://www.ncbi.nlm.nih.gov/pubmed/23637525
http://dx.doi.org/10.2147/CIA.S27931

Ejemplares similares